International Journal of Antimicrobial Agents 3 (1994) 281-283 281 © 1994 Elsevier Science BV 0924-8579/94/$26.00 Author Index Adam, D., Neonatal respiratory tract infections (3) Cockerill, F.R. see R. Patel (3) 215 S109 Cole, P., Evaluating clinical outcomes of respiratory Akalin, H.E., Atypical pneumonias: therapeutic infection (3) S15 possibilities (3) S75 Allen, B.W. see S.L. Chan (3) 267 Dattwyler, R.J. see B.J. Luft (3) 251 Amyes, S.G.B. see P.M.A. Shanahan (3) 259 De Clercq, E. see J. Neyts (3) 187 Andriole, V.T., Community-acquired respiratory De Pauw, B.E. see J.P. Donnelly (3) 245 infection: keeping patients at home (3) S67 DeJoy, S.Q., A.L. Oronsky, M.M. Wick and S.S. Aoun, M. and J. Klastersky, Respiratory infections Kerwar, Preclinical studies with platelet-activating in the immunocompromised patient (3) S99 factor antagonists in models of septic shock (3) 175 Arathoon, E.G., C.R. Mejia, R.M. Estrada y Del Brutto, O.H., Medical management of neuro- Martin, J.E. Hernandez, G.J. Turner and L.W. cysticercosis (3) 133 Kitchen, Serum HIV-1 p24 levels and body weight Dickinson, J.M. see S.L. Chan (3) 267 measurements before and after 4 weeks of diethyl- Donnelly, J.P. and B.E. De Pauw, Current infectious carbamazine treatment given to HIV-1 seroposi- complications and their management in acute leu- tive persons (3) 275 kemia and bone marrow transplantation (3) 245 DuPont, H.L. see E.G. Obot (3) 97 Bailey, R.R., A.H. Smith, B.A. Peddie and General Practitioners, Lomefloxacin compared with tri- Ellard, G.A. see S.L. Chan (3) 267 methoprim for the treatment of women with cysti- Estrada y Martin, R.M. see E.G. Arathoon (3) 275 tis (3) 129 Baiocchi, P. see M. Venditti (3) 123 Fera, M.T., M. Carbone and A. Foca, Activity of Bergogne-Bérézin, E., Interpretation of pharmacol- cefixime against Helicobacter pylori (3) 105 ogic data in respiratory tract infections (3) S3 Foca, A. see M.T. Fera (3) 105 Bleichner, G., O. Thomas and J.P. Sollet, Diarrhea in intensive care: diagnosis and treatment (3) 33 Genvresse, I. and C. Carbon, Cefixime (3) 1 Bosler, E.M. see B.J. Luft (3) 251 Giamarellou, H., Nosocomial pneumonia: patho- genesis, diagnosis, current therapy and prophylac- Camprubi, S. see J.M. Tomas (3) 61 tic approach (3) S87 Carbon, C. see I. Genvresse (3) 1 Grassi, G.G., Tetracyclines — extending the atypi- Carbon, C., Pneumonia in the elderly (3) S119 cal spectrum (3) $31 Carbone, M. see M.T. Fera (3) 105 Castagliuolo, I. see C. Pothoulakis (3) 17 Hernandez, J.E. see E.G. Arathoon (3) 275 Chan, S.L., W.W. Yew, J.H.D. Porter, K.P.W.J. McAdam, B.W. Allen, J.M. Dickinson, G.A. El- Julve, J. see J.M. Tomas (3) 61 lard and D.A. Mitchison, Comparison of Chinese and Western rifapentines and improvement of bio- Keating, M.R. see R. Patel (3) 215 availability by prior taking of various meals (3) Kelly, C.P. see C. Pothoulakis (3) 17 267 Kerr, J.R., In vitro activities of two drug combina- Chong, Y., K. Lee and O.H. Kwon, Antimicrobial tions of ceftazidime, cefotaxime, cefuroxime, cip- resistance patterns in Korea (3) 211 rofloxacin, chloramphenicol, imipenem and te- 282 mocillin against clinical isolates of Pseudomonas Pechére, J.-C., The use of macrolides in respiratory cepacia from patients with cystic fibrosis (3) 205 tract infections (3) S53 Kerwar, S.S. see S.Q. DeJoy (3) 175 Peddie, B.A. see R.R. Bailey (3) 129 Kitchen, L.W. see E.G. Arathoon (3) 275 Peltola, H., Respiratory infections in the young child Klastersky, J. see M. Aoun (3) 99 (3) S113 Kobayashi, H., N. Ohgaki and H. Takeda, Thera- Perani, M. see P.A. Miglioli (3) 65 peutic possibilities for diffuse panbronchiolitis (3) Porayko, M.K. see R. Patel (3) 215 S81 Porter, J.H.D. see S.L. Chan (3) 267 Kwon, O.H. see Y. Chong (3) 211 Potgieter, P. see E. Rubinstein (3) 47 Pothoulakis, C., I. Castagliuolo, C.P. Kelly and J.T. Labro, M.T., Interactions between antimicrobial LaMont, Clostridium difficile-associated diarrhea drugs and phagocytes: an overview (3) 73 and colitis: pathogenesis and therapy (3) 17 Lamonaca, V. see M. Venditti (3) 123 LaMont, J.T. see C. Pothoulakis (3) 17 Ragazzi, E. see P.A. Miglioli (3) 65 Lee, K. see Y. Chong (3) 211 Rubinstein, E. and P. Potgieter, Fluoroquinolones Llaurado, X. see J.M. Tomas (3) 61 in bronchopulmonary infections (3) $47 Ludwig, E., Controversies on pharmacokinetics of Rusthoven, J.J., Biological response modifiers and fluoroquinolones in elderly patients (3) 49 infectious diseases: Actual and potential therapeu- Luft, B.J., E.M. Bosler and R.J. Dattwyler, Lyme tic agents (3) 223 borreliosis (3) 251 Shanahan, P.M.A., C.J. Thomson and S.G.B. McAdam, K.P.W.J. see S.L. Chan (3) 267 Amyes, B-Lactam resistance in aerobic commensal Mejia, C.R. see E.G. Arathoon (3) 275 faecal flora (3) 259 Merino, S. see J.M. Tomas (3) 61 Smith, A.H. see R.R. Bailey (3) 129 Meunier, F. see M. Zervos (3) 147 Sollet, J.P. see G. Bleichner (3) 33 Miglioli, P.A., E. Ragazzi, M. Perani, C. Wool and Sugar, A.M. and J. Tjia, Effect of fluconazole on the P. Palatini, Penetration of carumonam into the interactions between human neutrophils and Can- pleural fluid: comparison of intravenous bolus and dida albicans (3) 171 constant infusion in rats with experimentally in- Surawicz, C.M., Ecological means of control of diar- duced pleurisy (3) 65 rhea (3) 89 Mitchison, D.A. see S.L. Chan (3) 267 Takeda, H. see H. Kobayashi (3) 81 Neyts, J. and E. De Clercq, Strategies for the treat- Tarasi, A. see M. Venditti (3) 123 ment and prevention of cytomegalovirus infec- Testore, G.P. see M. Venditti (3) 123 tions (3) 187 Thomas, O. see G. Bleichner (3) 33 Norrby, S.R., Clinical trials of antibiotics: need for Thomson, C.J. see P.M.A. Shanahan (3) 259 better investigators (3) 139 Tyia, J. see A.M. Sugar (3) 171 Tomas, J.M., S. Camprubi, S. Merino, R. Parés, X. Obot, E.G. and H.L. DuPont, Current approach to Llaurad6o and J. Julve, Inhibition of two imidazole the treatment of travellers’ diarrhoea (3) 97 antimycotics, eberconazole and clotrimazole, by Ohgaki, N. see H. Kobayashi (3) 81 different components of Candida albicans serotype Oronsky, A.L. see S.Q. DeJoy (3) 175 B membrane protoplasts (3) 61 Turner, G.J. see E.G. Arathoon (3) 275 Palatini, P. see P.A. Miglioli (3) 65 Pareés, R. see JM. Tomas (3) 61 Venditti, M., A. Tarasi, P. Baiocchi, V.L amonaca Patel, R., F.R. Cockerill, M.K. Porayko and M.R. and G.P. Testore, The activity ‘in vitro’ of trospec- Keating, Antibiotics may predispose to lactoba- tomycin against high-level antibiotic-resistant en- cillemia in liver transplant patients (3) 215 terococci (3) 123 283 Verhoef, J., Selective decontamination of the diges- Williams, J.D., Introduction (3) S1 tive tract for the prevention of infection (3) 109 Wool, C. see P.A. Miglioli (3) 65 Verhoef, J., New treatment modalities for serious Gram-negative bacterial infections (3) 115 Yew, W.W. see S.L. Chan (3) 267 Wick, M.M. see S.Q. DeJoy (3) 175 Zervos, M. and F. Meunier, Fluconazole (Dif- Williams, J.D., B-Lactam antibiotics in respiratory lucan®): a review (3) 147 tract infections (3) S21